Sotorasib 120mg Tablet
Global Shipping : Reliable Global Distribution Network
Express Delivery : Priority Shipping for Every Order
Secure Payments : Trusted Payment Protection System
Secure Handling
24/7 Worldwide Support
Global Access
Worldwide Access to Health
Cold-Chain Expert
Excellence in Cold-Chain
Trusted Supply
Certified Medical Supply
Indications & Clinical Uses
- Sotorasib, marketed as Lumakras in the United States (Lumykras in the European Union), is a targeted KRAS G12C inhibitor tablet made by Amgen.
- It is approved for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have already had at least one other systemic treatment, under the US accelerated-approval pathway, and, in combination with the antibody panitumumab, for KRAS G12C-mutated metastatic colorectal cancer after prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy.
- Treatment requires a confirmed KRAS G12C mutation on an FDA-approved test before starting.
- It is an oral, self-administered tablet taken at home rather than a hospital-given infusion, though regular clinic visits for blood tests and monitoring are required throughout treatment.
- It is not approved for children.
Side Effects
- When sotorasib is used alone for lung cancer, the most common side effects (each affecting one in five patients or more) are diarrhea, musculoskeletal pain, nausea, fatigue, cough and raised liver enzymes; when combined with panitumumab for colorectal cancer, rash, dry skin, diarrhea and mouth sores are also common.
- Sotorasib carries no boxed warning, but liver injury (hepatotoxicity) affects around a quarter of patients on monotherapy, so blood tests to check liver function are done every three weeks for the first three months, then monthly.
- A less common but serious effect is interstitial lung disease or pneumonitis, which can be fatal; tell your healthcare provider immediately about new or worsening cough, shortness of breath or fever, and about any yellowing of the skin or eyes.
Precautions & Warnings
- Liver function tests must be checked before starting sotorasib, every three weeks for the first three months, then monthly or as clinically indicated, since hepatotoxicity is common; treatment may be interrupted, reduced or stopped depending on severity.
- Sotorasib must be stopped immediately if interstitial lung disease or pneumonitis is suspected and permanently discontinued if confirmed.
- Take tablets whole, without crushing, chewing or splitting, at the same time each day, with or without food.
- Effective contraception is recommended during treatment and for a period after the last dose, and breastfeeding is not recommended during treatment or for one week afterward.
- Safety and effectiveness have not been established in children.
- Tell your healthcare provider about all other medicines, since dose adjustments or timing changes are often needed.
Avoid Interactions
- Do not take proton pump inhibitors or H2-receptor blockers with sotorasib, since reducing stomach acid lowers its absorption; if a locally acting antacid is unavoidable, take it at least four hours before or ten hours after sotorasib.
- Avoid strong or moderate CYP3A4 inducers, which can reduce sotorasib's effect.
- Sotorasib itself can lower the levels and effectiveness of many CYP3A4-metabolised medicines, including some hormonal contraceptives, so alternative contraception may be needed, and it can raise levels of sensitive P-glycoprotein substrate drugs such as digoxin, increasing the risk of side effects.
- Tell your healthcare provider and pharmacist about every prescription and over-the-counter medicine, herbal product and supplement you take before and during treatment.
References
Frequently Asked Questions
Sotorasib, sold as Lumakras, treats KRAS G12C-mutated non-small cell lung cancer in adults who have had prior treatment, and, combined with panitumumab, KRAS G12C-mutated colorectal cancer after earlier chemotherapy. A specific genetic test must confirm the KRAS G12C mutation before starting. It is taken as a once-daily tablet.
Sotorasib is taken as tablets by mouth once daily, at about the same time each day, with or without food. Swallow the tablets whole; do not crush, chew or split them. If you vomit or miss a dose, do not take an extra dose to make up for it.
The most common side effects of sotorasib are diarrhea, joint or muscle pain, nausea, tiredness, cough and raised liver enzymes. Liver injury and lung inflammation (pneumonitis) are less common but serious; tell your healthcare provider at once about new cough, breathlessness, fever, yellowing skin or eyes, or unusual tiredness.
Avoid proton pump inhibitors and H2-blockers such as omeprazole and famotidine, since they reduce sotorasib absorption; if needed, separate an antacid by several hours. Avoid strong CYP3A4 inducers, which lower its effect. Tell your healthcare provider about hormonal contraceptives and other regular medicines, since sotorasib can change how they work.
Yes. Liver function blood tests are done before starting sotorasib, every three weeks for the first three months, then monthly, because liver injury is common. Your healthcare provider may pause, lower or stop the dose depending on the results, so keep every scheduled blood test appointment.
No. Sotorasib can harm an unborn baby, so effective contraception is advised during treatment and for a time after the last dose for both men and women. Breastfeeding is not recommended during treatment or for one week afterward. It has not been studied in children.

Trusted & Reliable – Your Partner in Global Distribution.
We provide comprehensive lines of pharmaceutical products to support all your healthcare distribution needs.